Novel Therapeutics Targeting VEGF Pathways in Neovascular AMD
Overview
Emerging therapies for neovascular age-related macular degeneration (nAMD) focus on reducing treatment burden while maintaining or improving vision. Phase 3 trials of tyrosine kinase inhibitors (TKIs) such as EYP-1901 and OTX-TKI show promising results in extending treatment intervals and reducing supplemental injections compared to current anti-VEGF therapies.
Background
Neovascular AMD develops in approximately 10% of AMD patients but accounts for most severe vision loss. The pathogenesis involves choroidal neovascular membranes driven primarily by VEGF family ligands, with current treatments targeting VEGF-A. Despite efficacy, challenges remain including frequent injections and persistent fluid. New agents targeting broader VEGF receptors and additional pathways aim to improve durability and efficacy.
Data Highlights
| Drug | Mechanism/Target | Phase | Trial Name (NCT) | Status |
|---|---|---|---|---|
| EYP-1901 (EyePoint Pharmaceuticals) | Implant with pan-VEGFR and PDGF inhibition | 3 | LUCIA (NCT06683742), LUGANO (NCT06668064) | Recruiting |
| OTX-TKI (Ocular Therapeutix) | Selective inhibitor of VEGFR-1, VEGFR-2, VEGFR-3 | 3 | SOL-R (NCT06495918), SOL-1 (NCT06223958) | Recruiting / Active, not recruiting |
| CLS-AX (Clearside Biomedical) | Selective inhibitor of VEGFR-1, VEGFR-2, VEGFR-3 (suprachoroidal suspension) | 2 | ODYSSEY (NCT05891548) | Completed |
| KHL4951 (Kyowa Kirin Co) | Selective inhibitor of VEGFR-1, VEGFR-2, VEGFR-3 (topical) | 2 | NCT06116890 | Recruiting |
| D-4517.2 (Ashvattha Therapeutics) | Inhibition of microglia, macrophages, and RPE | 2 | TEJAS (NCT05387837) | Active |
Key Findings
- EYP-1901 implant demonstrated noninferiority to aflibercept every 8 weeks in phase 2, with 85%-89% reduction in treatment burden and only 56%-64% requiring rescue injections over 6 months.
- OTX-TKI showed an 89% reduction in treatment burden at 1 year with comparable visual acuity and retinal thickness; 33% of patients required no supplemental injections.
- Suprachoroidal axitinib (CLS-AX) achieved an 84% reduction in treatment burden in a phase 2b trial with stable vision and retinal anatomy.
- Multiple phase 3 trials (LUCIA, LUGANO, SOL-1, SOL-R) are ongoing to evaluate efficacy and safety of these TKIs compared to standard aflibercept treatment.
- Additional delivery methods including topical drops (KHL4951, PAN-90806) and subcutaneous injections (D-4517.2) are under investigation to further reduce treatment burden.
- Broader targeting of VEGF receptors and complementary pathways (PDGF, FGF, microglia/macrophage inhibition) may improve outcomes in recalcitrant or difficult-to-treat nAMD cases.
Clinical Implications
These novel therapeutics have the potential to significantly reduce injection frequency and treatment burden for patients with nAMD while maintaining visual outcomes. Clinicians should monitor ongoing phase 3 trial results to inform future treatment paradigms. Expanded targeting beyond VEGF-A may address limitations of current anti-VEGF monotherapies, especially in patients with persistent fluid or suboptimal response.
Conclusion
Emerging pan-VEGFR tyrosine kinase inhibitors and innovative delivery systems represent promising advances in nAMD management, aiming to enhance durability and efficacy. Ongoing pivotal trials will clarify their role in clinical practice.
References
- EyePoint Pharmaceuticals, Ocular Therapeutix, ClinicalTrials.gov 2023 -- Novel Therapeutics for Neovascular AMD
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.